Literature DB >> 8194839

Potential role for low dose limited-field radiation therapy (2 x 2 grays) in advanced low-grade non-Hodgkin's lymphomas.

G Ganem1, P Lambin, G Socié, T Girinsky, J Bosq, J L Pico, P Solal-Céligny, J M Cosset.   

Abstract

The purpose of this retrospective study was to evaluate the efficacy of low-dose limited field radiation therapy (LDLRT) in low-grade non-Hodgkin's lymphoma (NHL) patients, in order to outline its possible role. The rationale of the analysis was as follows: (1) there is no clear dose-response relationship for radiation therapy (RT) in localized low-grade non-Hodgkin's lymphomas (LGNHL); (2) long-term disease-free survival can be achieved in advanced LGNHL with low-dose (1.5-2 Gy) fractionated total body irradiation; (3) moreover, some of our previous LGNHL patients stopped their conventional planned RT course for convenience after 5 to 7.5 Gy and remained free from local progression in irradiated volumes for a long period of time. Patient selection criteria were the following: (1) patients with low-grade NHL (LGNHL); (2) patients who received no other form of therapy concomitantly with LDLRT until evaluation of the response; (3) patients who received a planned dose of 4 Gy in two fractions and over 3 days in a limited field. Out of 37 patients, 27 patients were fully evaluable. Twenty-two patients had stage III or IV disease. The median longevity of the disease was 73 months. Twenty-five patients had previously received chemotherapy (18 with anthracyclines). Nineteen patients had received one LDLRT course only. Eight patients responding to the first LDLRT had received at least one subsequent LDLRT course. After the first LDLRT course, an objective response in irradiated sites was observed in 24 of the 27 patients (89 per cent). Ten and 14 patients respectively demonstrated a complete response (CR) (37 per cent) and partial response (PR) (52 per cent). Freedom from progression in irradiated volumes for evaluable patients ranged from 4 to 35 months. Among the eight patients who received at least two LDLRT courses, a total of 20 different areas were irradiated, and 15 areas (75 per cent) showed a CR. Toxicity due to LDLRT was minimal. In conclusion, low-dose limited-field RT resulted in a high proportion of responses in LGNHL. The mechanisms explaining this radioresponsiveness are poorly understood. However, the efficacy of LDLRT could have several clinical applications in the general management of patients with advanced LGNHL.

Entities:  

Mesh:

Year:  1994        PMID: 8194839     DOI: 10.1002/hon.2900120102

Source DB:  PubMed          Journal:  Hematol Oncol        ISSN: 0278-0232            Impact factor:   5.271


  14 in total

1.  Radiotherapy of indolent orbital lymphomas : Two radiation concepts.

Authors:  Laila König; Robert Stade; Juliane Rieber; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2016-05-09       Impact factor: 3.621

Review 2.  [Significance of apoptotic processes in radiotherapy. II].

Authors:  M Abend; D van Beuningen
Journal:  Strahlenther Onkol       Date:  1998-04       Impact factor: 3.621

3.  [Radiation therapy (4 Gy vs. 24 Gy) in patients with indolent non-Hodgkins lymphoma: Results of the FORT Study].

Authors:  Klaus Herfarth; Laila König
Journal:  Strahlenther Onkol       Date:  2014-10       Impact factor: 3.621

Review 4.  Advanced-stage III/IV follicular lymphoma: treatment strategies for individual patients.

Authors:  Frank Heinzelmann; Hellmut Ottinger; Marianne Engelhard; Martin Soekler; Michael Bamberg; Martin Weinmann
Journal:  Strahlenther Onkol       Date:  2010-04-26       Impact factor: 3.621

5.  Intraoperative radiation therapy for a patient with bulky disease of mesenteric non-Hodgkin's lymphoma.

Authors:  H Yamaue; H Tanimura; H Terasawa; Y Nakatani; T Tsunoda; M Tani; M Iwahashi
Journal:  Surg Today       Date:  1998       Impact factor: 2.549

6.  Low dose palliative radiotherapy for refractory aggressive lymphoma.

Authors:  Osamu Tanaka; Masahiko Oguchi; Takayoshi Iida; Senji Kasahara; Hideko Goto; Takeshi Takahashi
Journal:  Rep Pract Oncol Radiother       Date:  2016-08-24

7.  Response rates and recurrence patterns after low-dose radiotherapy with 4 Gy in patients with low-grade lymphomas.

Authors:  Laila König; Juliane Hörner-Rieber; Denise Bernhardt; Adriane Hommertgen; Stefan Rieken; Jürgen Debus; Klaus Herfarth
Journal:  Strahlenther Onkol       Date:  2018-02-15       Impact factor: 3.621

8.  Low-dose radiation therapy (2 Gy × 2) in the treatment of orbital lymphoma.

Authors:  Carolina E Fasola; Jennifer C Jones; Derek D Huang; Quynh-Thu Le; Richard T Hoppe; Sarah S Donaldson
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-05-29       Impact factor: 7.038

9.  Response to low-dose involved-field radiotherapy in patients with non-Hodgkin's lymphoma.

Authors:  S K Luthy; A K Ng; B Silver; K O Degnan; D C Fisher; A S Freedman; P M Mauch
Journal:  Ann Oncol       Date:  2008-07-22       Impact factor: 32.976

10.  Efficacy of low-dose radiotherapy (2 Gy × 2) in the treatment of marginal zone and mucosa-associated lymphoid tissue lymphomas.

Authors:  Marzia Cerrato; Erika Orlandi; Angelisa Vella; Sara Bartoncini; Giuseppe C Iorio; Diego Bongiovanni; Francesco Capriotti; Carola Boccomini; Francesco Vassallo; Chiara Cavallin; Viola De Luca; Francesca R Giglioli; Umberto Ricardi; Mario Levis
Journal:  Br J Radiol       Date:  2021-06-16       Impact factor: 3.039

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.